Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hanrath

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Journal of Cardiovascular Electrophysiology|July 28, 2007
Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillationFelix Gramley, Johann Lorenzen, Jurgita Plisiene, et al.
Journal of the American College of Cardiology|October 4, 2005
Selective increase of cardiac neuronal sympathetic tone: a catheter-based access to modulate left ventricular contractilityMarkus Zarse, Jurgita Plisiene, Karl Mischke, et al.
International Journal of Cardiology|October 27, 2006
Imaging of the coronary venous system: retrograde coronary sinus angiography versus venous phase coronary angiogramsKarl Mischke, Christian Knackstedt, Georg Mühlenbruch, et al.
Thrombosis Research|January 31, 2006
Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trialCaroline Schmidt-Lucke, W Dieter Paar, Christoph Stellbrink, et al.
American Heart Journal|April 23, 2005
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMETChristian Torp-Pedersen, Philip A Poole-Wilson, Karl Swedberg, et al.
Journal of the American College of Cardiology|May 10, 2006
A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cellsRüdiger Blindt, Felix Vogt, Irina Astafieva, et al.
Cardiovascular Drugs and Therapy|May 27, 2004
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)John G F Cleland, Kevin Goode, Leif Erhardt, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 17, 2021
Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET)Michael Nabauer, Michael Oeff, Andrea Gerth, et al.
Lancet (London, England)|July 11, 2003
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialPhilip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al.
American Heart Journal|September 26, 2006
A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantationPeter W Radke, Hans R Figulla, Helmut Drexler, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Journal of Cardiovascular Electrophysiology|July 28, 2007
Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillationFelix Gramley, Johann Lorenzen, Jurgita Plisiene, et al.
Journal of the American College of Cardiology|October 4, 2005
Selective increase of cardiac neuronal sympathetic tone: a catheter-based access to modulate left ventricular contractilityMarkus Zarse, Jurgita Plisiene, Karl Mischke, et al.
International Journal of Cardiology|October 27, 2006
Imaging of the coronary venous system: retrograde coronary sinus angiography versus venous phase coronary angiogramsKarl Mischke, Christian Knackstedt, Georg Mühlenbruch, et al.
Thrombosis Research|January 31, 2006
Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trialCaroline Schmidt-Lucke, W Dieter Paar, Christoph Stellbrink, et al.
American Heart Journal|April 23, 2005
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMETChristian Torp-Pedersen, Philip A Poole-Wilson, Karl Swedberg, et al.
Journal of the American College of Cardiology|May 10, 2006
A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cellsRüdiger Blindt, Felix Vogt, Irina Astafieva, et al.
Cardiovascular Drugs and Therapy|May 27, 2004
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)John G F Cleland, Kevin Goode, Leif Erhardt, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 17, 2021
Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET)Michael Nabauer, Michael Oeff, Andrea Gerth, et al.
Lancet (London, England)|July 11, 2003
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialPhilip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al.
American Heart Journal|September 26, 2006
A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantationPeter W Radke, Hans R Figulla, Helmut Drexler, et al.
Pageof 12